MDXH

MDxHealth SA [MDXH] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

MDXH Stock Summary

Top 10 Correlated ETFs

MDXH

Top 10 Correlated Stocks

MDXH

In the News

MDXH Financial details

Company Rating
-
Market Cap
63.31M
Income
-46.09M
Revenue
70.19M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
252
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-2.35
Forward P/E
-
PEG
0.54
P/S
2.13
P/B
6.3
P/C
-
P/FCF
-4.5
Quick Ratio
2.19
Current Ratio
2.42
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.78
EPS next Y
-
EPS next Q
-
EPS this Y
-47.47%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-24.77%
Revenue last 5Y
42.89%
Revenue Q/Q
0.25%
EPS Q/Q
5.41%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-35%
ROE
-209%
ROC
-0.26%
Gross Margin
60%
Oper. Margin
-47%
Profit Margin
-75%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.35-4.64
52W High
-
52W Low
-
RSI
56
Rel Volume
0.55
Avg Volume
75.74K
Volume
41.56K
Perf Week
1.87%
Perf Month
-0.91%
Perf Quarter
8.46%
Perf Half Y
9%
-
-
-
-
Beta
-379815
-
-
Volatility
0.01%, 0.08%
Prev Close
-0.46%
Price
2.18
Change
-0.46%

Something similar

Top by Market Cap
TSLA
AMZN
LLY.SW
BRYN.DE
TL0.DE
Top Correlated ETFs
AFIF
Top Correlated Stocks
ACGLO
WEYS
CMS-PB
QUAD
PSTG
Similar Market Cap
STWK.ST
OPI
VSAC
ARBK
0342.HK

Company Profile

Healthcare Medical - Diagnostics & Research
  • Volume Average 75.74K
  • Market Capitalization 63.31M
  • Employee 252
  • CEO Mr. Michael K. McGarrity
  • Headquarters Herstal,BE
  • IPO Date 2021-11-04
  • Website https://mdxhealth.com

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.